Efficacy, safety, adherence and persistence of PCSK9 inhibitors in clinical practice: a single country, multicenter, observational study (AT-TARGET-IT)

Abstract Background PCSK9 inhibitors (PCSK9i) significantly decrease LDL cholesterol (LDL-C), either as monotherapy or in addition to the maximally tolerated dose of statin and/or ezetimibe. Yet, few data are available on efficacy and background lipid-lowering therapy (LLT) adjustment in patients tr...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	European heart journal 2023-11, Vol.44 (Supplement_2)
Hauptverfasser:	Gargiulo, P, Basile, C, Calabro', P, Catalano, A, Merlini, P A, Iannuzzo, G, Ciccone, M M, Paloscia, L, Varbella, F, Brunetti, N D, Paolillo, S, Marzano, F, Indolfi, C, Perrone-Filardi, P
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!